Manuel DaFonseca

Affiliations

Sonnet BioTherapeutics, Inc, Princeton, NJ, United States.

Publications (1)

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.

Frontiers in immunology

Avec: Richard T Kenney , John K Cini , Susan Dexter , Manuel DaFonseca , Justus Bingham , Isabelle Kuan , Sant P Chawla , Thomas M Polasek , Jason Lickliter , Philip J Ryan

Réseau de co-auteurs

Richard T Kenney 1 collaboration

John K Cini 1 collaboration

Susan Dexter 1 collaboration

Justus Bingham 1 collaboration

Isabelle Kuan 1 collaboration

Sant P Chawla 1 collaboration

Thomas M Polasek 1 collaboration

Jason Lickliter 1 collaboration

Philip J Ryan 1 collaboration